share_log

BioVie | 424B5: Prospectus

BioVie | 424B5: Prospectus

BioVie | 424B5：募資說明書
美股SEC公告 ·  2024/10/29 11:38

Moomoo AI 已提取核心訊息

BioVie Inc., a clinical-stage company focusing on the development of drug therapies for liver disease and neurological disorders, has announced the offering of 1,146,000 shares of its Class A common stock. The shares are being offered at a price of $2.83 per share, with ThinkEquity LLC acting as the exclusive placement agent for the offering. ThinkEquity LLC is not purchasing or selling any securities but will use reasonable efforts to arrange for the sale. The placement agent has agreed to a placement agent fee as outlined in the offering's terms. The proceeds from the offering are expected to be used for working capital and general corporate purposes. The offering is expected to close on or about October 29, 2024, subject to customary...Show More
BioVie Inc., a clinical-stage company focusing on the development of drug therapies for liver disease and neurological disorders, has announced the offering of 1,146,000 shares of its Class A common stock. The shares are being offered at a price of $2.83 per share, with ThinkEquity LLC acting as the exclusive placement agent for the offering. ThinkEquity LLC is not purchasing or selling any securities but will use reasonable efforts to arrange for the sale. The placement agent has agreed to a placement agent fee as outlined in the offering's terms. The proceeds from the offering are expected to be used for working capital and general corporate purposes. The offering is expected to close on or about October 29, 2024, subject to customary closing conditions. BioVie's common stock is traded on The Nasdaq Capital Market under the symbol 'BIVI.' As of October 28, 2024, the aggregate market value of BioVie's outstanding common stock held by non-affiliates was approximately $47.7 million. The company has previously sold approximately $12.67 million of securities in the 12 months preceding the date of the prospectus supplement, excluding the current offering.
BioVie公司是一家臨床階段公司，專注於開發治療肝病和神經疾病的藥物療法，已宣佈發行1,146,000股A類普通股。每股價格爲2.83美元，ThinkEquity LLC擔任該發行的獨家配售代理。ThinkEquity LLC不購買或出售任何證券，但將盡力安排銷售。配售代理已同意按照發行條款中規定的配售代理費用支付。 預計發行所得將用於營運資金和一般企業用途。 該發行預計將於2024年10月29日左右結束，視乎慣例的閉市條件。 BioVie普通股在納斯達克資本市場交易，代碼爲'BIVI.' 到2024年10月28日爲止，BioVie尚未進行關聯方持有的普通股的市值約爲4770萬美元。 除本次發行外，公司在擬補充招股說明書日期之前的12個月內銷售了約1267萬美元的證券。
BioVie公司是一家臨床階段公司，專注於開發治療肝病和神經疾病的藥物療法，已宣佈發行1,146,000股A類普通股。每股價格爲2.83美元，ThinkEquity LLC擔任該發行的獨家配售代理。ThinkEquity LLC不購買或出售任何證券，但將盡力安排銷售。配售代理已同意按照發行條款中規定的配售代理費用支付。 預計發行所得將用於營運資金和一般企業用途。 該發行預計將於2024年10月29日左右結束，視乎慣例的閉市條件。 BioVie普通股在納斯達克資本市場交易，代碼爲'BIVI.' 到2024年10月28日爲止，BioVie尚未進行關聯方持有的普通股的市值約爲4770萬美元。 除本次發行外，公司在擬補充招股說明書日期之前的12個月內銷售了約1267萬美元的證券。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Aditxt
    ADTX
    -- 10.2200
    Black Diamond Therapeutics
    BDTX
    -- 2.220
    TC BioPharm
    TCBP
    -- 2.1300
    Biodexa Pharmaceuticals
    BDRX
    -- 2.3800
    CNS Pharmaceuticals
    CNSP
    -- 4.1800
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    3月議息會議來襲，市場將迎來轉折點？
    美聯儲本次利率決議將如何影響美股短期走勢？你會如何調整投資組合？ 展开
    FOMC新聞發佈會，2025年1月29日